Peter Foley has served as an investigator, speaker, advisor, or received travel/grant/research support from 3M, Abbott, AbbVie, Akaal, Amgen, Arcutis, Ascent, Aspen, AstraZeneca, Australian Ultraviolet Services, Biogen Idec, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene, Celtaxsys, Clinuvel, Cutanea, Dermira, CSL, Eli Lilly and Company, Galderma, Genentech, GlaxoSmithKline/Stiefel, Hexima, iNova, Janssen-Cilag, LEO Pharma/Peplin, Merck Serono, Merck Sharp & Dohme, Novartis, Regeneron, Reistone, Roche, Sanofi, Schering-Plough/Merck Sharp & Dohme, Sun Pharma, UCB Pharma, Valeant, and Wyeth/ Pfizer.
Funding: This study was supported by Eli Lilly and Company.
Funding: This study was supported by Eli Lilly and Company.
ACKNOWLEDGMENT
The authors would like to acknowledge Lahari Na, M. Pharm,
Eli Lilly and Company, for her writing assistance with the
preparation of this manuscript. Medical writing support was also
provided by Andrew Sakko, PhD, CMPP, and editorial support
was provided by Dana Schamberger, MA, of Syneos Health
and funded by Eli Lilly and Company in accordance with Good
Publication Practice (GPP3) guidelines (www.ismpp.org/gpp3).
REFERENCES
1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Derm. 1999;41:401-407.
2. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305-1314.
3. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008;17:1297-1302.
4. Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26:235-239.
5. Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Derm. 2014;71:633-641.
6. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
7. Villacorta R, Teeple A, Lee S, et al. A multinational assessment of workrelated productivity loss and indirect costs from a survey of patients with psoriasis. British J Dermatol. 2020;183:548-558.
8. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-193.
9. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med. 2016;375:345-356.
10. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541-551.
11. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med. 2016;375:2102.
12. Naegeli A, Gaich C, Zhu B, et al. The psoriasis skin appearance bothersomeness measure (PSAB) for patients with moderate-to-severe plaque psoriasis. American Academy of Dermatology 72nd Annual Meeting Denver, Colorado. March 21-25, 2014. Abstract P8674.
13. Wu JJ, Lin C, Sun L, et al. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereol. 2019;33:318-324.
14. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, doubleblind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87.
15. Edson-Heredia E, Banerjee S, Zhu B, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30:864-865.
16. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166:861-872.
17. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PloS One. 2012;7:e52935.
18. Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. Arch Derm Res. 2019;311:453-460.
19. Langley RGB, Reich K, Strand V, et al. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020;29:369-380.
2. Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305-1314.
3. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008;17:1297-1302.
4. Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26:235-239.
5. Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Derm. 2014;71:633-641.
6. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
7. Villacorta R, Teeple A, Lee S, et al. A multinational assessment of workrelated productivity loss and indirect costs from a survey of patients with psoriasis. British J Dermatol. 2020;183:548-558.
8. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-193.
9. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med. 2016;375:345-356.
10. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541-551.
11. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med. 2016;375:2102.
12. Naegeli A, Gaich C, Zhu B, et al. The psoriasis skin appearance bothersomeness measure (PSAB) for patients with moderate-to-severe plaque psoriasis. American Academy of Dermatology 72nd Annual Meeting Denver, Colorado. March 21-25, 2014. Abstract P8674.
13. Wu JJ, Lin C, Sun L, et al. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereol. 2019;33:318-324.
14. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, doubleblind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87.
15. Edson-Heredia E, Banerjee S, Zhu B, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30:864-865.
16. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166:861-872.
17. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PloS One. 2012;7:e52935.
18. Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. Arch Derm Res. 2019;311:453-460.
19. Langley RGB, Reich K, Strand V, et al. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020;29:369-380.
AUTHOR CORRESPONDENCE
Melinda J. Gooderham MD mgooderham@centrefordermatology.com
